Skip to content
DataLookout
Menu

NCT06132256

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 18 words Show 5 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Nov 2026 to Sep 10, 2026
    • Primary completion date changed from estimate of Sep 2026 to Aug 27, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised at 6 of 78 sites
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 135 to confirmed 145
    • Study sites: 82 to 78
    v17
  3. Minor Study sites revised (82)v16
  4. Minor Study sites: 74 to 82v15
  5. Minor Study sites: 73 to 74v14
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Study sites: 72 to 73v13
  2. Minor Study sites: 69 to 72v12
  3. Notable Primary completion date: Apr 2025 to Sep 2026
    • Study sites: 67 to 69
    • Study completion date: Jun 2025 to Nov 2026
    v11
  4. Minor Study sites: 62 to 67v10
  5. Minor Study sites: 69 to 62v9
  6. Minor Study sites: 63 to 69v8
  7. Minor Study sites: 40 to 63v7
  8. Minor Study sites: 23 to 40v6
  9. Minor Study title expanded, about 1 wordv5
  10. Minor Study sites: 3 to 23v4
  11. Minor Study sites: 2 to 3v3
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Nov 2023 to Dec 11, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])
Timeframe: Baseline through Week 26

Secondary (4)

Time to disease progression
Annualized rate of decline in FVC percent predicted over 26 weeks
Change in St. George's Respiratory Questionnaire (SGRQ) score from Baseline to Week 26
Change in diffusion capacity for carbon monoxide (DLco % of predicted, corrected for hemoglobin) from Baseline to Week 26

Arms and interventions

AxatilimabExperimental

Participants will receive axatilimab every 2 weeks during the 26-week Treatment Period.

PlaceboPlacebo comparator

Participants will receive placebo every 2 weeks during the 26-week Treatment Period.

Drugs: Axatilimab

Other: Placebo

Sites

78 sites in 13 countries

Spain 15, Italy 11, South Korea 11, Australia 8, Germany 7, United Kingdom 6, Taiwan 5, France 4, Poland 4, Belgium 2, Canada 2, Romania 2, Czechia 1